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Growing evidence from multiple retrospective cohorts in-
dicates that hospitalised COVID-19 patients often could
suffer from an excessive coagulation activation leading to
an increased risk of venous and arterial thrombosis (includ-
ing small calibre vessels) and a poor clinical course [1].
Notably, D-dimer level at the time of hospital admission is
a predictor of the risk of development of acute respirato-
ry distress syndrome (ARDS) [2], the risk of intensive care
admission and the risk of death [3]. An observational study
among COVID-19 patients with elevated D-dimer levels
at baseline showed that the 28-day mortality was lower in
those receiving heparin than in those who did not [4].
Based on the available literature and published recom-
mendations from the International Society of Thrombosis
and Hemostasis (https://www.isth.org), from the American
Society of Hematology (https://www.hematology.org/
covid-19) and from the Society for Thrombosis and
Haemostasis Research (http://gth-online.org), the Working
Party on Hemostasis (Swiss Society of Hematology) pro-
poses the following recommendations for pharmacological
thromboprophylaxis in COVID-19 patients in the acute
setting. Suggestions will be regularly updated:
– All in-hospital COVID-19 patients should receive phar-
macological thromboprophylaxis according to a risk
stratification score, unless contraindicated.
– In patients with creatinine clearance >30 ml/min, low
molecular weight heparin (LMWH) should be adminis-
tered according to the prescribing information. An in-
creased dose should be considered in overweight pa-
tients (>100 kg).
– In patients with creatinine clearance <30 ml/min, un-
fractionated heparin (UHF) subcutaneously twice or
three times daily or intravenously should be adminis-
tered according to the prescribing information. An in-
creased dose should be considered in overweight pa-
tients (>100 kg).
– Anti-Xa activity should be monitored when indicated
(e.g., evidence of renal dysfunction).
– Antithrombin need not be monitored but this could be
considered on an individual basis in cases of dissemi-
nated intravascular coagulation or sepsis-induced coag-
ulopathy or heparin resistance.
– We suggest regularly monitoring prothrombin time, D-
dimers, fibrinogen, the platelet count, lactate dehydro-
genase (LDH), creatinine and alanine aminotransferase
(ALT) (daily or at least 2−3 times per week).
– In patients in intensive care with a large increase in D-
dimers, severe inflammation, or signs of hepatic or re-
nal dysfunction or imminent respiratory failure, inter-
mediate or therapeutic dosing of LMWH or UHF
should be considered, according to the bleeding risk.
– Heparin-induced thrombocytopenia (HIT) should be
considered in patients with fluctuations in platelet
counts or signs of heparin resistance.
– In patients undergoing extracorporeal membrane oxy-
genation (ECMO) treatment we suggest maintaining
UFH at doses bringing anti-Xa activity into the thera-
peutic range.
– There are no data on the use of direct oral anticoagu-
lants.
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